Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Zymogenetics Inc patents


Recent patent applications related to Zymogenetics Inc. Zymogenetics Inc is listed as an Agent/Assignee. Note: Zymogenetics Inc may have other listings under different names/spellings. We're not affiliated with Zymogenetics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "Z" | Zymogenetics Inc-related inventors


Il-31 antibody compositions

The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. ... Zymogenetics Inc

Methods of treating skin disorders using anti-il-31ra antibodies

The present invention relates to methods of treating patients suffering from contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination by administering an il-31ra antagonist.. . ... Zymogenetics Inc

Use of il-31 monoclonal antibodies for antagonizing signal transduction in dorsal root ganglion cells

Use of antagonists to il-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. ... Zymogenetics Inc

Use of il-31ra monoclonal antibodies for antagonizing signal transduction in dorsal root ganglion cells

Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. ... Zymogenetics Inc

Zcytor17 heterodimeric cytokine receptor monoclonal antibodies

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.. ... Zymogenetics Inc

Use of il-31 monoclonal antibodies for reducing pruritus

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.. ... Zymogenetics Inc

Methods of producing a zcytor17 heterodimeric cytokine receptor

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.. ... Zymogenetics Inc

Methods of treating skin disorders using anti-il-31ra antibodies

The present invention relates to methods of treating patients suffering from contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination by administering an il-31ra antagonist.. . ... Zymogenetics Inc

Homogeneous preparations of il-31

Homogeneous preparations of human and murine il-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.. ... Zymogenetics Inc

Compositions and methods for modulating immune responses

The present invention provides a newly identified b7 receptor, zb7r1 that functions as lymphocyte inhibitory receptor, which is a pd-1-like molecule and is expressed on t cells. The present invention also provides the discovery of zb7r1's ability to bind to cd155. ... Zymogenetics Inc

Methods of treating atopic dermatitis with il-31 monoclonal antibodies

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.. ... Zymogenetics Inc

Methods of treating inflammation using il-17a and il-17f cross-reactive monoclonal antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease. ... Zymogenetics Inc

Soluble hybrid fcgamma receptors and related methods

Disclosed are soluble hybrid fcγ receptor (fcγr) polypeptide compositions and related methods of using such polypeptides to treat igg-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid fcγr polypeptides.. ... Zymogenetics Inc

Homogeneous preparations of il-28 and il-29

Homogeneous preparations of il-28a, il-28b, and il-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. ... Zymogenetics Inc

07/20/17 / #20170204190

Zcytor17 heterodimeric cytokine receptor monoclonal antibodies

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.. ... Zymogenetics Inc

07/06/17 / #20170190780

Use of il-31ra monoclonal antibodies for treating neuronal inflammation

Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. ... Zymogenetics Inc

07/06/17 / #20170190771

Use of il-31 monoclonal antibodies for treating neuronal inflammation

Use of antagonists to il-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. ... Zymogenetics Inc

06/29/17 / #20170182160

Methods of treating atopic dermatitis with il-31 monoclonal antibodies

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for il-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human il-31. ... Zymogenetics Inc

05/18/17 / #20170137525

Methods of treating skin disorders using an anti-il-31ra antibody

The present invention relates to methods of treating patients suffering from contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination by administering an il-31ra antagonist.. . ... Zymogenetics Inc

05/11/17 / #20170129952

Method of reducing pruritus using il-31 monoclonal antibodies

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.. ... Zymogenetics Inc

04/06/17 / #20170096466

Homogeneous preparations of il-31

Homogeneous preparations of human and murine il-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.. ... Zymogenetics Inc

02/16/17 / #20170044253

Use of il-31 monoclonal antibodies for treating atopic dermatitis

The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.. ... Zymogenetics Inc

02/09/17 / #20170037123

Anti-human il-21 antibodies

Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity. ... Zymogenetics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Zymogenetics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Zymogenetics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###